Literature DB >> 27045154

Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.

Susan J Appel, Rosemary J Cleiment.   

Abstract

Approximately 5-10% of breast cancer cases appear in families at a higher rate and at an earlier onset than in the average population. Two known gene defects, BRCA1 and BRCA2, account for the majority of these hereditary related breast cancers. Additionally, BRCA1 and BRCA2 are related to the Hereditary Breast and Ovarian Cancer syndrome (HBOC), where risk for other related cancers are increased. Various health-care professional organizations provide guidelines that speak to the need for conducting risk assessments, but little research has been conducted focusing on the initial screening for this syndrome. This quality improvement project attempts to determine if Nurse Navigators can effectively perform the initial education and screening for HBOC syndrome within a mammography and women's breast imaging setting using a simplified patient history tool. E. M. Rodgers' Diffusion of Innovation model, a map of how new ideas and programs have become adopted and accepted, guided this project's development and implementation. Over the course of 8 weeks, 1,420 women seeking service at 3 mammography and imaging sites were given a new risk assessment tool for HBOC. Additionally, the use of Nurse Navigation to identify women who may be at risk for HBOC was implemented. Two populations seeking service at the study sites were evaluated: (1) women obtaining breast screening/imaging services and (2) women receiving breast biopsy results. Patients identified as "at-risk" were defined by evidence-based practice guidelines from the National Comprehensive Cancer Network and were referred for further genetic evaluation by a genetic professional. During this initial implementation of the HBOC risk assessment program, low participation of screening/imaging patients requesting HBOC education and evaluation occurred (129 screening patients or 9%). High rates of positive biopsy patients (5 patients or 34.7%) werefound to be at risk for HBOC compared to similar studies. Identifying HBOC risk at the time of breast biopsy results gave the opportunity to impact the timing and kind of surgical management of patients at risk for this syndrome.The Commission on Cancer (CoC), an arm of the American College of Surgeons, provides practice guideline standards and accreditation for cancer programs. Patients will become more familiar with being assessed for HBOC and other hereditary cancers during their annual health-care visits and more identification of patients at riskfor HBOC should occur as new CoC 2012 standards requiring hereditary cancer risk assessments for a cancer program's certification are enacted.

Entities:  

Mesh:

Year:  2015        PMID: 27045154

Source DB:  PubMed          Journal:  J Natl Black Nurses Assoc        ISSN: 0885-6028


  3 in total

1.  A Survey of the Awareness and Educational Needs of Nurses in Nagasaki Prefecture Regarding Hereditary Breast and Ovarian Cancer.

Authors:  Megumi Matsumoto; Noriko Sasaki; Yayoi Tsukigawa; Ryota Otsubo; Hiroshi Yano; Takeshi Nagayasu
Journal:  J Cancer Educ       Date:  2022-01-06       Impact factor: 2.037

2.  Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.

Authors:  Tarsha Jones; Anne Marie McCarthy; Younji Kim; Katrina Armstrong
Journal:  Cancer Med       Date:  2017-06-19       Impact factor: 4.452

3.  A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results.

Authors:  Laura Cortesi; Bruna Baldassarri; Stefano Ferretti; Elisabetta Razzaboni; Mariangela Bella; Lauro Bucchi; Debora Canuti; Pierandrea De Iaco; Giorgio De Santis; Fabio Falcini; Vania Galli; Lea Godino; Maurizio Leoni; Anna Myriam Perrone; Marco Pignatti; Gianni Saguatti; Donatella Santini; Priscilla Sassoli de'Bianchi; Federica Sebastiani; Mario Taffurelli; Giovanni Tazzioli; Daniela Turchetti; Claudio Zamagni; Carlo Naldoni
Journal:  Cancer Med       Date:  2020-02-11       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.